Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
J Nutr Biochem ; 24(11): 1798-809, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23773624

ABSTRACT

Recent evidence indicates that several metabolic abnormalities developed during obesity are associated with the presence of dysfunctional adipose tissue. Diet is a key factor that modulates several functions of adipose tissue; however, each nutrient in the diet produces specific changes. Thus, the aim of this work was to study the effect of the interaction of the type (coconut or soybean oil) and amount (5% or 10%) of fat with the type of dietary protein (casein or soy protein) on the functionality of white adipose tissue of Zucker (fa/fa) rats. The results showed that soybean oil reduced adipocyte size and decreased esterified saturated fatty acids in white adipose tissue. Excess dietary fat also modified the composition of esterified fatty acids in white adipose tissue, increased the secretion of saturated fatty acids to serum from white adipose tissue and reduced the process of fatty acids re-esterification. On the other hand, soy protein sensitized the activation of the hormone-sensitive lipase by increasing the phosphorylation of this enzyme (Ser 563) despite rats fed soy protein were normoglucagonemic, in contrast with rats fed casein that showed hyperglucagonemia but reduced hormone-sensitive lipase phosphorylation. Finally, in white adipose tissue, the interaction between the tested dietary components modulated the transcription/translation process of lipid and carbohydrate metabolism genes via the activity of the PERK-endoplasmic reticulum stress response. Therefore, our results showed that the type of protein and the type and amount of dietary fat selectively modify the activity of white adipose tissue, even in a genetic model of obesity.


Subject(s)
Adipose Tissue, White/metabolism , Dietary Fats/pharmacology , Dietary Proteins/pharmacology , Adipocytes/cytology , Adipose Tissue, White/drug effects , Animals , Caseins/metabolism , Caseins/pharmacology , Cell Size , Coconut Oil , Endoplasmic Reticulum Stress/physiology , Fatty Acids/metabolism , Fatty Acids, Nonesterified/blood , Male , Plant Oils/pharmacology , RNA, Messenger/metabolism , Rats , Rats, Zucker , Soybean Oil/pharmacology , Soybean Proteins/metabolism , Soybean Proteins/pharmacology
2.
Nutr Res ; 29(10): 728-35, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19917453

ABSTRACT

Several studies have evaluated the effect of soy protein or soluble fiber on serum cholesterol in hypercholesterolemic subjects, with different results. We hypothesized that this response is associated with the presence of polymorphisms in genes encoding proteins involved in lipoprotein metabolism or reverse cholesterol transport. Thus, the aims of the present work were to study the effectiveness of a dietary portfolio consisting of a combination of soy protein and soluble fiber integrated in a low saturated fat (LSF) diet on blood lipids in a Mexican group with hyperlipidemia and to determine the association between responsiveness to the diet and the frequency of apolipoprotein (Apo) E and ApoA1 and ABCG5/8 polymorphisms. Forty-three hyperlipidemic subjects (20 men and 23 women) were given an LSF diet for 1 month, followed by an LSF diet that included 25 g of soy protein and 15 g of soluble fiber daily for 2 months. After the 3-month dietary intervention, serum total cholesterol (TC) significantly decreased by 20.6%, and serum triglycerides (TGs) decreased by 40.4%. Fifty-one percent of the subjects had a reduction more than 20% in serum TC, and 77% of the subjects had a reduction more than 20% in serum TG (hyperresponders). Approximately 14% of the hypercholesterolemic subjects had the ABCG8 (52 G/C) polymorphism, 65% had the ABCG5 (1950 C/G and G/G) polymorphism, 53.5% had the ApoA1 (-75 G/A and A/A) polymorphism, and 23.3% had the ApoE (3/4) polymorphism. Independently of genotype, the combination of cholesterol-lowering foods in an LSF diet significantly reduced serum TC and TG in Mexican hypercholesterolemic subjects.


Subject(s)
Dietary Fiber/therapeutic use , Hyperlipidemias/diet therapy , Hyperlipidemias/genetics , Hypolipidemic Agents/therapeutic use , Lipoproteins/genetics , Soybean Proteins/therapeutic use , ATP Binding Cassette Transporter, Subfamily G, Member 5 , ATP-Binding Cassette Transporters/genetics , Adult , Apolipoprotein A-I/genetics , Apolipoproteins E/genetics , Cholesterol/blood , Cholesterol/genetics , Diet, Fat-Restricted , Dietary Fiber/pharmacology , Female , Humans , Hyperlipidemias/blood , Hypolipidemic Agents/pharmacology , Lipids/blood , Lipids/genetics , Male , Mexico , Middle Aged , Polymorphism, Single Nucleotide , Prospective Studies , Soybean Proteins/pharmacology , Triglycerides/blood , Triglycerides/genetics
3.
Rev Invest Clin ; 59(6): 458-69, 2007.
Article in Spanish | MEDLINE | ID: mdl-18402338

ABSTRACT

The adenine monophosphate (AMP) activated protein kinase (AMPK), is a heterotrimeric complex that is activated by an increase in the AMP/ATP ratio, and is considered to be a cellular energy sensor that contributes to regulate energy balance and caloric intake. AMPK is activated by LKB1 hinase and it can phophorylate several enzymes involved in anabolism to prevent further ATP consumption, and induces some catabolic enzymes to increase ATP generation. Furthermore, AMPK regulates the expression of genes involved in lipogenesis and mitochondrial biogenesis, among others. AMPK is distributed in most organs including, liver, skeletal muscle, heart and hypothalamus; and even in adipose cells. In addition, AMPK is activated in the hypothalamus stimulating appetite due to energy depletion. AMPK also participates in glycolysis regulation, glucose uptake, lipid oxidation, fatty acid synthesis, cholesterol synthesis and gluconeogenesis, and it has been considered as a possible target enzyme in the treatment of some diseases such as obesity, type 2 diabetes and hepatic steatosis. This review provides a general overview of AMPK structure, its activators and its function in the organism.


Subject(s)
Adenylate Kinase/physiology , Energy Metabolism/physiology , Adenosine Monophosphate/metabolism , Adenosine Triphosphate/metabolism , Adenylate Kinase/antagonists & inhibitors , Adenylate Kinase/chemistry , Adipokines/physiology , Adipose Tissue/metabolism , Animals , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/enzymology , Diabetes Mellitus, Type 2/physiopathology , Enzyme Activation/drug effects , Fatty Liver/drug therapy , Fatty Liver/enzymology , Fatty Liver/physiopathology , Glucose/metabolism , Humans , Hypoglycemic Agents/pharmacology , Hypothalamus/metabolism , Lipogenesis/physiology , Liver/metabolism , Myocardium/metabolism , Obesity/drug therapy , Obesity/enzymology , Obesity/physiopathology , Organ Specificity , Phosphorylation , Physical Exertion/physiology , Protein Processing, Post-Translational
SELECTION OF CITATIONS
SEARCH DETAIL
...